COR vs. NVS
COR (Cencora Inc.) and NVS (Novartis AG) are both stocks. Both are in the Healthcare sector — COR in Medical Distribution, NVS in Drug Manufacturers - General. Over the past 10 years, COR returned 17.47%/yr vs 11.14%/yr for NVS. At a 0.27 correlation, their price movements are largely independent.
Performance
COR vs. NVS - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, COR achieves a -16.27% return, which is significantly lower than NVS's 14.40% return. Over the past 10 years, COR has outperformed NVS with an annualized return of 17.47%, while NVS has yielded a comparatively lower 11.14% annualized return.
COR
- 1D
- 0.07%
- 1M
- 10.42%
- YTD
- -16.27%
- 6M
- -18.27%
- 1Y
- -3.81%
- 3Y*
- 17.14%
- 5Y*
- 20.65%
- 10Y*
- 17.47%
NVS
- 1D
- -0.55%
- 1M
- 2.22%
- YTD
- 14.40%
- 6M
- 18.98%
- 1Y
- 30.60%
- 3Y*
- 19.57%
- 5Y*
- 14.77%
- 10Y*
- 11.14%
COR vs. NVS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
COR Cencora Inc. | -16.27% | 51.48% | 10.37% | 25.33% | 26.26% | 44.09% | 23.37% | 23.51% | -17.57% | 19.51% |
NVS Novartis AG | 14.40% | 46.95% | 0.02% | 16.14% | 8.06% | -3.65% | 3.34% | 13.92% | 5.95% | 19.42% |
Correlation
The correlation between COR and NVS is 0.28, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.28 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.28 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.35 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.34 |
Correlation (All Time) Calculated using the full available price history since Nov 7, 1996 | 0.27 |
Fundamentals
COR:
$55.03B
NVS:
$293.28B
COR:
$13.07
NVS:
$6.99
COR:
21.55
NVS:
21.90
COR:
10.24
NVS:
1.48
COR:
0.17
NVS:
5.29
COR:
16.20
NVS:
7.62
COR:
$328.68B
NVS:
$56.05B
COR:
$11.66B
NVS:
$42.19B
COR:
$3.64B
NVS:
$22.40B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
COR vs. NVS — Risk / Return Rank
COR
NVS
COR vs. NVS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Cencora Inc. (COR) and Novartis AG (NVS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| COR | NVS | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.60 | ||
| Sortino ratioReturn per unit of downside risk | -2.06 | ||
| Omega ratioGain probability vs. loss probability | 1.01 | 1.26 | -0.25 |
| Calmar ratioReturn relative to maximum drawdown | -0.12 | 2.43 | -2.55 |
| Martin ratioReturn relative to average drawdown | -0.33 | 5.88 | -6.21 |
Loading charts...
Drawdowns
COR vs. NVS - Drawdown Comparison
The maximum COR drawdown since its inception was -71.01%, which is greater than NVS's maximum drawdown of -42.10%. Use the drawdown chart below to compare losses from any high point for COR and NVS.
Loading charts...
Drawdown Indicators
| COR | NVS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -71.01% | -42.10% | -28.91% |
Max Drawdown (1Y)Largest decline over 1 year | -32.44% | -12.65% | -19.79% |
Max Drawdown (3Y)Largest decline over 3 years | -32.44% | -19.95% | -12.49% |
Max Drawdown (5Y)Largest decline over 5 years | -32.44% | -20.42% | -12.02% |
Max Drawdown (10Y)Largest decline over 10 years | -32.44% | -26.03% | -6.41% |
Current DrawdownCurrent decline from peak | -24.54% | -6.46% | -18.08% |
Average DrawdownAverage peak-to-trough decline | -13.62% | -10.92% | -2.70% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 11.68% | 5.23% | +6.45% |
Volatility
COR vs. NVS - Volatility Comparison
The current volatility for Cencora Inc. (COR) is 6.51%, while Novartis AG (NVS) has a volatility of 7.18%. This indicates that COR experiences smaller price fluctuations and is considered to be less risky than NVS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| COR | NVS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.51% | 7.18% | -0.67% |
Volatility (6M)Calculated over the trailing 6-month period | 26.93% | 14.96% | +11.97% |
Volatility (1Y)Calculated over the trailing 1-year period | 30.20% | 21.02% | +9.18% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 22.30% | 18.89% | +3.41% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 27.48% | 19.64% | +7.84% |
Dividends
COR vs. NVS - Dividend Comparison
COR's dividend yield for the trailing twelve months is around 0.83%, less than NVS's 3.12% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
COR Cencora Inc. | 0.83% | 0.67% | 0.93% | 0.96% | 1.13% | 5.13% | 6.74% | 7.48% | 2.07% | 1.61% | 1.77% | 1.17% |
NVS Novartis AG | 3.12% | 2.90% | 3.84% | 3.44% | 3.70% | 3.86% | 3.22% | 3.03% | 3.47% | 3.24% | 3.73% | 3.10% |
Financials
COR vs. NVS - Financials Comparison
This section allows you to compare key financial metrics between Cencora Inc. and Novartis AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
COR vs. NVS - Profitability Comparison
COR - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Cencora Inc. reported a gross profit of 3.59B and revenue of 78.36B. Therefore, the gross margin over that period was 4.6%.
NVS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Novartis AG reported a gross profit of 10.07B and revenue of 13.52B. Therefore, the gross margin over that period was 74.4%.
COR - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Cencora Inc. reported an operating income of 1.14B and revenue of 78.36B, resulting in an operating margin of 1.5%.
NVS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Novartis AG reported an operating income of 4.24B and revenue of 13.52B, resulting in an operating margin of 31.3%.
COR - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Cencora Inc. reported a net income of 1.64B and revenue of 78.36B, resulting in a net margin of 2.1%.
NVS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Novartis AG reported a net income of 3.16B and revenue of 13.52B, resulting in a net margin of 23.3%.
Frequently Asked Questions
COR and NVS have a correlation of 0.28, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NVS has higher volatility (7.18%) compared to COR (6.51%). In terms of maximum drawdown, COR dropped -71.01% vs NVS's -42.10%.
NVS currently has the higher Sharpe Ratio (1.47 vs -0.13), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for COR and NVS
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer